A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This study aims to confirm if patients with a specific biomarker might have a better response
to secukinumab treatment. To meet this purpose, exploratory biomarker studies will be done.
The goals of these exploratory studies are to (1) find biomarkers that will identify persons
with rheumatoid arthritis who will have the best possible response to secukinumab and (2) to
identify persons who will have fewer side effects in order to maximize their benefit from
secukinumab.